MIRA Pharmaceuticals Appoints Andriy Mushak as Fractional CFO
MIRA is trading near its 52-week low of $0.9 (11% above the low).
Summary
MIRA Pharmaceuticals appointed Andriy Mushak as its new fractional CFO, bringing extensive SEC reporting and capital markets experience, which is vital for the company's financial stability and future capital raises.
Key Events · Executive and Board Changes · MIRA
-
CFO Departure
Alan Weichselbaum stepped down as Chief Financial Officer, effective June 6, 2026. The company stated his departure was not due to any disagreements.
-
Fractional CFO Appointment
Andriy Mushak was appointed as the new fractional Chief Financial Officer, effective June 6, 2026.
-
Expertise and Role
Mr. Mushak is a Certified Public Accountant with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. He will oversee financial reporting, SEC compliance, audit readiness, and capital-raising support.
-
Compensation Structure
Mr. Mushak will provide services through LMAM Consulting Group, LLC for $6,000 per month, operating as an independent contractor.
Analysis · MIRA · Life Sciences
MIRA Pharmaceuticals has appointed Andriy Mushak, a seasoned CPA and consulting partner, as its new fractional Chief Financial Officer. This appointment is significant for the company, which recently issued a 'going concern' warning, as Mr. Mushak's expertise in SEC reporting, audit readiness, and capital markets support directly addresses critical financial management needs. His role is essential for maintaining compliance and supporting future capital-raising efforts, allowing the company to continue advancing its drug pipeline.
At the time of this filing, MIRA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.